FDA Rejects Moderna’s mRNA Flu Vaccine Application Amidst Broader Policy Shifts

The Food and Drug Administration (FDA) refused to review Moderna’s application for the first mRNA-based flu vaccine, a decision that has sparked controversy and accusations of a politically motivated “anti-vaccine agenda.” The rejection, initially communicated via a “refusal-to-file” letter dated February 3, 2026, raises questions about the future of mRNA vaccine development and the influence of current federal health officials on public health practices.

The Application and the FDA’s Initial Response

In December 2025, Moderna submitted its application to the FDA seeking approval for an mRNA flu vaccine designed for adults aged 50 and older. The vaccine had undergone clinical trials involving over 40,000 participants. However, the FDA, under the direction of officials including Vinay Prasad, rejected the application without a full review. Prasad reportedly overruled FDA staff, including David Kaslow, the head of the vaccine office, who had written a memo recommending the application be reviewed [1].

A Revised Regulatory Approach

The FDA initially reversed its rejection when Moderna proposed splitting the application, seeking full approval for the vaccine’s use in people aged 50 to 64 and an accelerated approval for use in people 65 and up. The accelerated approval pathway requires Moderna to conduct an additional trial in the 65+ age group to confirm effectiveness post-market. [1]

Concerns of Political Interference

Experts suggest the FDA’s initial rejection stemmed from more than just scientific concerns. The decision aligns with Health and Human Services Secretary Robert F. Kennedy Jr.’s broader skepticism towards vaccines, particularly those utilizing mRNA technology. Kennedy and his allies have reportedly expressed safety concerns without providing supporting data and have reduced funding for mRNA vaccine research [2].

Some officials have questioned the rationale behind the rejection, suggesting the FDA is “coming up with reasons” to disapprove mRNA vaccines [3]. The agency’s focus on the design of the clinical trial – specifically, the use of a standard flu shot in the control group instead of a high-dose version for those over 65 – has been described as “pretext and obfuscation” by some legal experts [3].

Industry Impact and Future Implications

The FDA’s actions are already impacting the vaccine industry. Moderna has reportedly lost over $700 million in federal contracts for pandemic vaccine development. Industry investors and vaccine makers express concerns that Kennedy’s efforts are “chilling” innovation, leading companies to abandon research and reduce their workforce [2]. Moderna’s president, Stephen Hoge, stated that there will be “less invention, investment, and innovation in vaccines generally, across all the companies” [4].

The rejection of Moderna’s application underscores a significant shift in public health policy and raises concerns about the future of mRNA vaccine development. The situation highlights the tension between scientific advancement and political influence within regulatory agencies.